Multiple significant clinical trial results have emerged across oncology disciplines. NRG Oncology’s Phase II data shows proton therapy combined with emission correlates with enhanced survival in glioblastoma patients, advancing to Phase III. Merck’s pulmonary arterial hypertension drug Winrevair reduced clinical worsening risk by 76% in newly diagnosed patients. Opus Genetics’ early promising data from a gene augmentation therapy trial in congenital blindness paves way for FDA discussions. Enanta Pharmaceuticals reported subgroup efficacy in a Phase IIb RSV trial despite missing primary endpoint, with plans for further studies. These findings highlight advancements in cancer and inflammatory disease treatments with potential to improve patient outcomes.